An official website of the United States government
SNV1521 in Participants with Advanced Solid Tumors
Trial Status: active
This study is testing a new medicine, SNV1521, for people with advanced cancers. The
researchers want to find out if SNV1521 is safe, well-tolerated, and effective in
treating solid tumors. They are investigating different doses in order to find the most
effective and safe one. They are also investigating whether it can be combined with other
cancer therapies.
Inclusion Criteria
Advanced or metastatic solid tumor malignancy
Evaluable or Measurable disease (RECIST 1.1 Criteria).
ECOG Performance Status 0 or 1.
Life expectancy > 3 months
Exclusion Criteria
History of other malignancy within the past 2 years
Prior diagnosis of Myelodysplastic syndrome or Acute Myeloid Leukemia
Significant cardiovascular disease within 6 months
Significant gastrointestinal disease
HIV infection with a CD4+ T-cell count < 200 cells/μL and/or a detectable viral load
Liver dysfunction
Additional locations may be listed on ClinicalTrials.gov for NCT06220864.
